



UNIVERSITY OF LEEDS

This is a repository copy of *Ondansetron and irritable bowel syndrome*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/97314/>

Version: Accepted Version

---

**Other:**

Luthra, P and Ford, AC (2015) Ondansetron and irritable bowel syndrome. BMJ Publishing Group.

<https://doi.org/10.1136/gutjnl-2014-307551>

---

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

## TITLE PAGE

**Title:** Ondansetron and Irritable Bowel Syndrome.

**Authors:** Pavit Luthra<sup>1</sup>, Alexander C Ford<sup>1, 2</sup>.

<sup>1</sup>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.

<sup>2</sup>Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.

**Correspondence:** Dr. Alex Ford

Leeds Gastroenterology Institute

Room 125

4<sup>th</sup> Floor

Bexley Wing

St. James's University Hospital

Beckett Street

Leeds

United Kingdom

LS9 7TF

Email: [alex12399@yahoo.com](mailto:alex12399@yahoo.com)

Telephone: +441132684963

Facsimile: +441132429722

**Abbreviations:** 5-HT 5-hydroxytryptamine

FDA Food and Drug Administration

GI gastrointestinal

IBS-D diarrhoea-predominant irritable bowel syndrome

**Keywords:** Irritable bowel syndrome

5-hydroxytryptamine

Ondansetron

**Word count:** 469

Editor;

We read the paper by Garsed *et al*,<sup>1</sup> which revives interest in 5-hydroxytryptamine (5-HT) receptor antagonists as treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). As a highly prevalent functional gastrointestinal (GI) disorder,<sup>2</sup> without a known organic pathology to target, IBS continues to be challenging to treat. Interest in agents acting on 5-HT receptors selectively is not novel, with alosetron, the most well studied 5-HT<sub>3</sub> antagonist, demonstrating efficacy in treating IBS-D.<sup>3</sup> However, cases of severe constipation and ischaemic colitis led to the withdrawal of the drug. Ondansetron first demonstrated effects on GI transit over twenty years ago.<sup>4</sup> Given the known clinical effectiveness<sup>4</sup> of 5-HT<sub>3</sub> antagonists in IBS, and the good safety profile of ondansetron, it is perhaps surprising that no randomised controlled trial has been conducted previously.

At a time when licensed treatment options for IBS-D are lacking, we would like to congratulate the authors for performing this trial. The study demonstrated a significant improvement in stool form, the primary endpoint, a reduction in the number of days with urgency, and reduced urgency scores with ondansetron, compared with placebo. When applying the Food and Drug Administration (FDA) guidelines for assessing pharmacological agents in treating IBS,<sup>5</sup> ondansetron achieved a greater percentage of stool and pain responders (41%), than placebo (17%), although this result was not statistically significant. Unfortunately, there was no significant effect on abdominal pain, with FDA pain response criteria met by 43% with ondansetron, and 40% with placebo. Adverse events were limited with both treatments, although rates of constipation were higher with ondansetron. Reassuringly, no cases of ischaemic colitis were seen, although this is not surprising given the relatively small sample size.

Whilst the findings are important and may alter clinical practice, there are some limitations of the study. As with all crossover studies, there is the problem of carryover and order effects between crossover periods, which often cannot be completely adjusted for. Despite the 2 to 3-week washout period between treatments, the heterogeneous, fluctuating nature of IBS, along with high placebo response rates,<sup>6</sup> makes it difficult to be sure that there is no carryover between treatment periods. In addition, patient dropout rates were almost double in the arm receiving active treatment first, as compared to the arm receiving placebo first, suggesting an order effect, where patient dropout may be influenced by the sequence of treatment. These dropouts were omitted from the final analysis of the study, and hence a true intention-to-treat analysis was not carried out.

With this in mind, we feel the efficacy of ondansetron in treating IBS-D could be better judged if the authors had presented dichotomous data for pain and stool response for all 61 patients receiving ondansetron, and all 59 receiving placebo in the first treatment period, prior to crossover, with all dropouts assumed to be treatment failures.

“The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Gut and any other BMJPGJL products to exploit all subsidiary rights, as set out in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence-forms>).

**Authors:** Pavit Luthra<sup>1</sup>, Alexander C Ford<sup>1,2</sup>.

<sup>1</sup>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.

<sup>2</sup>Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.

### **Competing Interests:**

None.

### **REFERENCES**

1. Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, Henry A, Hall I, Whorwell P, Spiller R. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. *Gut* 2013; doi: 10.1136/gutjnl-2013-305989. [Epub ahead of print].
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. *Clin Gastroenterol Hepatol* 2012;10:712-721.
3. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT<sub>3</sub> Antagonists and 5-HT<sub>4</sub> Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. *Am J Gastroenterol* 2009;104:1831-1843.
4. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, MacCarty RL, Ciociola A. GR 38032F (ondansetron), a selective 5HT<sub>3</sub> receptor antagonist, slows colonic transit in healthy man. *Dig Dis Sci* 1990;35:477-80.

5. U.S Department of Health and Human Services. Food and Drug Administration. *Guidance for Industry: Irritable Bowel Syndrome- Clinical Evaluation for Drugs for Treatment*. <http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf> (accessed April 2014).
  
6. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. *Aliment Pharmacol Ther* 2010;32:144-158.